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CD4+ T-cell counts were further analyzed.
Results: Totally 291 HIV-infected cases were enrolled. Their mean ages
were 35.9 (standard deviation; 9.4) years, male：female ratio；254
(87.3%)：37(12.7%). Among them, 98.8% (168/170) showed CMV IgG posi-
tivity. Ninety-five patients (32.6%) had CD4+T cell count >Z500 cells/
uL; 156 patients (53.6%), >Z200 - <500cells/uL; and 40 patients
(13.7%), <200cells/uL. In addition, 23 (7.9%) patients had HIV viral load
>Z100,000 copies/ml; 98 patients (33.7%), >Z400 - <100,000; 50 pa-
tients (17.1%), >Z20 - <400; and 120 patients (41.2%), < 20 copies/ml.
Among them, 268 cases (92.1%) had negative CMV DNA detection, 16 cases
(5.5%) had detectable CMV DNA (<150 copies/mL), and 7 cases (2.4%) had
CMV DNA>150 copies/ml. Patients who had CD4+ T cell counts<200 cells/
uL have 5 times of odds ratio to develop CMV viremia, compared to sub-
jects who have CD4+ T cell counts > 500 cells/uL. Patients who had
HIV viral load >100,000 copies/ml have 129 times of odds ratio to develop
CMV viremia, compared to subjects who have HIV viral load <20
copies/ml.
Conclusion: Early initiation of highly active antiretroviral therapy would
prompt the recovery of immune deficiency, and certainly alleviate the
burden of CMV viremia.Table Demographic Features and Treatment Outcome
Characteristics MSM (NZ43) IDU and others (NZ11) P value
Age (years)PS 2-338
CLINICAL EXPERIENCES IN INTERPRETATION OF HIV-1 WESTERN BLOT
INDETERMINATE RESULTS
Kuo-Chen Weng a, Shu-Yuan Ho a, Sui-Yuan Chang a,b. aDepartments of
Laboratory Medicine, National Taiwan University Hospital, Taiwan;
bDepartment of Clinical Laboratory Sciences and Medical Biotechnology,
National Taiwan University, Taiwan
Purpose: According to the guidelines published by Taiwan Centers for Dis-
ease Control, status of HIV infection has to be confirmed by a positive West-
ern blot (WB) results after the HIV-1/2 antibody screening assay. However,
the interpretation of WB results might vary according to the package inserts
of the commercial manufacturers, which might cause disagreement between
different clinical laboratories.
Methods: The clinical outcomes of 1712 patients whose specimens were sent
for HIV WB tests between May 2006 and April 2012 were analyzed. The BIO-
RAD NEW LAV BLOT I, II was used by the Virology laboratory of the National
Taiwan University Hospital.
Results: Between the study period, a total of 1712 HIV WB-I tests were per-
formed, which include 1015 positive, 285 indeterminate, and 412 negative
results. For those who are determined as HIV WB-I positive, they are sero-
positive for GP160 (NZ1,014), GP110/120 (NZ995), P68/66 (NZ973), P55
(NZ885), P52/51 (NZ941), GP41 (NZ945), P40 (NZ602), P34/31
(NZ902), P24/25 (NZ937), and P18/17 (NZ679). For the indeterminate
HIV WB-I, four patterns are most common and they are P24/25 (NZ46),
P18/17 (NZ26), GP160 + P55 + P24/25 (NZ22), and P55 (NZ22). Among
the 22 patients reactive with GP160 + P55 + P24/25, 20(91%) are confirmed
with HIV infection status and two were lost of follow-up.
For HIV WB-II, among the 228 tests, none was positive. 98 are indeterminate
and 130 are negative. Most of the indeterminate HIV WB-II are sero-positive
with P26(NZ57). None of them are confirmed with HIV-2 infection at the end
of the study period.
Conclusions: Based on the study results, for those who have indeterminate
WB results, two or more interpretation criteria are suggested to help inter-
pretation, such WHO CRITERIA: 2ENV  GAG  POL and US CENTER FOR DIS-
EASE CONTROL CRITERIA: ENV + P24 / 25.Median [IQR] 34 (30e40) 43 (41e51) .011
Ongoing ART
Any 41 (95.3%) 5 (45.5%) < .001
Last HIV-1 RNA (copies/mL)
<40 32/40 (80.0%) 4/11 (36.4%) .009
HCV Genotype
GT1 11/31 (35.5%) 7/10 (70.0%) .075
GT2 18/31 (58.1%) 2/10 (20.0%) .067
GT6 0/31 (0.0%) 1/10 (10.0%) .244
Treatment Outcome
RVR 17/26 (65.4%) 3/6 (50.0%) .647PS 2-339
HIV-1 CRF08_BC MUTANTS RESISTANT TO REVERSE TRANSCRIPTASE
INHIBITORS
Hao Wu, Xiao-Min Zhang, Bo-Jian Zheng. Department of Microbiology, The
University of Hong Kong, Hong Kong
Purpose: Human immunodeficiency virus type (HIV)-1 circulating recombi-
nant form 08_BC (CRF08_BC), carrying recombinant reverse transcriptase
(RT) gene from subtype B and C, has recently become highly prevalent in
Southern China. As the number of patients infected by CRF08_BC increases,it is important to characterize the drug resistance mutations of CRF08_BC,
especially against widely used antiretrovirals.
Methods: In this study, clinically isolated virus was propagated in human pe-
ripheral blood mononuclear cells (PBMCs) with increasing concentrations of
nevirapine (NVP), efavirenz (EFV) or lamivudine (3TC).
Results: Three different resistance patterns led by initial mutations of
Y181C, E138G and Y188C were detected after in vitro selection with NVP. Vi-
rus variants with initial mutations, in combination with three other previ-
ously reported substitutions (K20R, D67N, V90I, K101R/E, V106I/A, V108I,
F116L, E138R, A139V, V189I, G190A, D218E, E203K, H221Y, F227L, N348I
and T369I) or novel mutations (V8I, S134N, C162Y, L228I, Y232H, E396G
and D404N) developed during NVP selection. EFV-associated variations con-
tained two initial mutations (L100I and Y188C) and three other mutations
(V106L, F116Y and T139V). Phenotypic analyses showed that E138R, Y181C
and G190A contributed high level resistance to NVP, while L100I and V106L
significantly reduce virus susceptibility to EFV. Y188C resulted in a 20-fold
reduction of susceptibility to both NVP and EFV. M184V was selected by
3TC as expected. This mutation, alone or with V90I or D67N, decreased
3TC susceptibility by over 1000 folds.
Conclusion: These results have brought new insight into the development of
drug-related mutations in patients and provided useful information for the
optimization of antiretroviral regimens.PS 2-340
PEGYLATED INTERFERON/RIBAVIRIN TREATMENT HIGHLY EFFECTIVE IN
HIV/HCV-COINFECTED MEN WHO HAVE SEX WITH MEN IN TAIWAN: SINGLE
MEDICAL CENTER EXPERIENCE
Wen-wei Ku a, Yea-yuan Chang b, Chih-hao Chang c, Bor-shen Hu d, Wong-
wing Wai b. aDivision of Infectious Diseases, Taipei Veterans General Hospital,
Hsinchu Branch, Hsinchu, Taiwan; bDivision of Infectious Diseases, Taipei
Veterans General Hospital, Taipei, Taiwan; cDivision of Gastroenterology,
Taipei Veterans General Hospital, Taipei, Taiwan; dDivision of Infectious
Diseases, Taipei City Hospital, Heping Branch, Taipei, Taiwan
Purpose: A recent outbreak of HCV infection has been identified among HIV-
infected men who have sex with men (MSM) worldwide, including Taiwan
since 2006. Pegylated interferon (PEG-IFN) with ribavirin (RBV) remains stan-
dard of treatment in most Asian countries. However, very few studies have
evaluated the treatment efficacy in such particular population.
Methods: We conducted a single-centered, retrospective cohort study of
HIV-1 infected patients in Northern Taiwan from 2006 to 2014. Persistent
HCV infection was diagnosed with positive anti-HCV serology and a detect-
able HCV viral load. Clinical characteristics, HIV-1 infection status, use of
antiretroviral therapy (ART), HCV genotypes, and IL-28B genotypes were
collected at baseline, during PEG-IFN plus RBV treatment, and at follow-up.
Results: Fifty-four patients had persistent HCV infection, of whom 43 were
MSM. They were significantly younger and received ART with an undetectable
HIV-1 viremia more often than the other cohort (Table). Thirty-four MSM were
eligible for treatment and had a very high sustained virological response (SVR)
rate regardless of HCV genotypes (80.0% [4/5] for GT 1, 100.0% [7/7] for non-
GT 1, p Z .417). Skin manifestations (local injection reaction and alopecia),
anemia, and depression were the most frequent adverse effects.EVR 21/21 (100.0%) 5/5 (100.0%) NA
SVR 18/19 (94.7%) 0/1 (0.0%) .100
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coinfected MSM in Taiwan, more aggressive treatment with PEG-IFN plus
RBV should be considered.PS 2-341
HIGH RATE OF HIV-1 DRUG RESISTANCE IN TREATMENT-EXPERIENCED
PATIENTS IN SOUTHERN TAIWAN, 2009-2014.
Hung-Chin Tsai a,b, I-Tzu Chen a,b, Ya-Wei Weng a,b, Chih-Chen Chou a,b,
Wei-Cheng Lin a,b, Yu-Ting Tseng a,b, Kuan-Sheng Wu a,b, Cheng-Len Sy a,b,
Jui-Kuang Chen a,b, Susan Shin-Jung Lee a,b, Yao-Shen Chen a,b. aSection of
Infectious Diseases, Kaohsiung Veterans General Hospital, Kaohsiung,
Taiwan; bNational Yang -Ming University, Taipei, Taiwan
Purpose: Genotype testing for HIV-1 drug resistance is useful for selecting
antiretroviral drug regimens for patients experiencing therapeutic failure.
The aim of the present study is to monitor the resistance trend in treat-
ment-experienced patients to guide the antiretroviral therapy in southern
Taiwan.
Methods: A retrospective cohort study on HIV-1 drug resistance was con-
ducted in antiretroviral therapy -experienced HIV-1 einfected individuals
at Kaohsiung Veterans General Hospital from 2009 to 2014. Genotypic
drug resistance was determined by ViroSeqTM system. Risk factor for
drug resistance was analyzed by Chi-square or Fisher’s exact tests,
and non-categorical variables were compared using the Mann-Whitney U
test
Results: From 2009 to 2014, a total of 65 patients had tested for resis-
tance, of whom 87% were infected by MSM, and 13% were infected by het-
erosexual. The prevalence rate for syphilis infection was 45%, hepatitis A
18%, hepatitis B 8% and hepatitis C 3%. Subtype B HIV-1strains were found
in 86% of the individuals, subtype CRF01_AE in 11% and subtype C in 3%.
The resistance rates to any three classes of antiretroviral therapy (NRTI,
NNRTI and PI) were 94%. The prevalence rate for NRTI, NNRTI and PI resis-
tance was 72%, 77% and 9%, respectively. The most common NRTI resis-
tance associated mutation was M184V (65%) and L74V (17%).The most
common NNRTI resistance associated mutation was K103N (29%), Y181C
(29%) and V179D (20%). The most PI resistance associated mutation was
A71T (17%), A71V (12%) and L10I (8%). The presence of drug resistance
was associated with longer duration of current failing anti-retroviral ther-
apy (pZ0.036).Figure. Frequency of NRTI, NNRTI and PI-associated mutation (%).
Conclusions: Our findings showed a high rate of antiretroviral drug resis-
tance in patient failure to the first line anti-retroviral therapy in southern
Taiwan. This result could better guide us in the development of efficacious
and effective management plans and strategies for treatment failure
patients.PS 2-342
INVESTIGATION OF YMDD MOTIF ANALYSIS FOR SIMULTANEOUS
DETECTION OF HBV GENOTYPE AND LAMIVUDINE RESISTANCE
Ya-Ting Yang a, Wei-Fang Chen a, Yi-Li Shih a, Ya-Chien Hung a, Chung-
Hsu Lai a,b,c, Hsi-Hsun Lin b. aDivision of Infection Control Laboratory,
Taiwan; bDivision of Infectious Diseases, E-Da Hospital/I-Shou University,
Kaohsiung City, Taiwan; cGraduate Institute of Medicine, College of
Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan
Purpose: The aim of this study is to investigate the YMDD motif amplification
and sequencing for detection of HBV genotype and Lamivudine resistance
simultaneously.
Methods: The YMDD motif was amplified by polymerase chain reaction (PCR)
with specific primers and the products were sequenced. The sequence of
YMDD motif was analyzed by “The genotype” software of the NCBI
(http://www.ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi) for HBV
genotyping and detection of 3TC resistance (YMDD motif analysis). RFLP of
the S gene was also performed for HBV genotyping and comparison with
the results of YMDD motif analysis. HBV viral load was measured by the
COBAS TaqMan 48 Real-Time PCR System.
Results: A total of 90 HBsAg positive specimens with vial load >1000 IU/ml
were included for study. By YMDD motif analysis, 60 genotype (GT-) B
(66.7%), 29 GT-C (33.2%), and 1 GT-D (1.1%) were identified and these results
were 100% in accordance with the results obtained by RFLP (Figure). Eighty-
seven (96.7%) were YMDD wild-type, 2 (2.2%) were YVDD mutant, and 1
(1.1%) was YIDD mutant.
Conclusions: YMDD motif analysis is a simple and accurate method for simul-
taneous detection of HBV genotype and Lamivudine resistance.
